These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 14968807)
1. Society of neuroscience-33rd annual meeting: metabotropic glutamate receptors. Danysz W IDrugs; 2004 Jan; 7(1):9-14. PubMed ID: 14968807 [No Abstract] [Full Text] [Related]
2. Psychiatric drugs. Excited by glutamate. Holden C Science; 2003 Jun; 300(5627):1866-8. PubMed ID: 12817119 [No Abstract] [Full Text] [Related]
3. The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. Koltunowska D; Gibula-Bruzda E; Kotlinska JH Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():242-9. PubMed ID: 23623810 [TBL] [Abstract][Full Text] [Related]
4. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. Beister A; Kraus P; Kuhn W; Dose M; Weindl A; Gerlach M J Neural Transm Suppl; 2004; (68):117-22. PubMed ID: 15354397 [TBL] [Abstract][Full Text] [Related]
5. The role of glutamate in the pathophysiology of Parkinson's disease. Blandini F; Greenamyre JT; Nappi G Funct Neurol; 1996; 11(1):3-15. PubMed ID: 8936453 [No Abstract] [Full Text] [Related]
6. Highlights from the Fifth International Meeting on Metabotropic Glutamate Receptors, held September 18-23, 2005, in Taormina, Sicily, Italy. Metabotropic glutamate receptors as therapeutic targets. Guitart X; Khurdayan VK Drug News Perspect; 2005 Nov; 18(9):587-93. PubMed ID: 16421632 [TBL] [Abstract][Full Text] [Related]
7. Society for neuroscience-33rd annual meeting. Hannan AJ IDrugs; 2004 Jan; 7(1):7-8. PubMed ID: 14968806 [No Abstract] [Full Text] [Related]
8. Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions. Jansen M; Dannhardt G Eur J Med Chem; 2003; 38(7-8):661-70. PubMed ID: 12932897 [TBL] [Abstract][Full Text] [Related]
9. [Modern aspects of investigation and clinical application of glutamatergic agents]. Petrov VI; Onishchenko NV Eksp Klin Farmakol; 2002; 65(4):66-70. PubMed ID: 12449079 [TBL] [Abstract][Full Text] [Related]
11. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Kew JN; Kemp JA Psychopharmacology (Berl); 2005 Apr; 179(1):4-29. PubMed ID: 15731895 [TBL] [Abstract][Full Text] [Related]
12. Memantine as a neuroprotective agent in early phases of psychosis. Fusar-Poli P; Pellegrini F; Cortesi M Med Hypotheses; 2007; 68(2):459-60. PubMed ID: 17005328 [No Abstract] [Full Text] [Related]
13. Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Kozela E; Pilc A; Popik P Psychopharmacology (Berl); 2003 Jan; 165(3):245-51. PubMed ID: 12442203 [TBL] [Abstract][Full Text] [Related]
14. Society of neuroscience-33rd annual meeting: neurological disorders. Taylor DP IDrugs; 2004 Jan; 7(1):15-8. PubMed ID: 14968808 [No Abstract] [Full Text] [Related]
15. N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system. Quintão NL; da Silva GF; Antonialli CS; de Campos-Buzzi F; Corrêa R; Filho VC Anesth Analg; 2010 Mar; 110(3):942-50. PubMed ID: 20185671 [TBL] [Abstract][Full Text] [Related]